Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rVWF:rFVIII and rVWF in treatment of bleeding episodes in von Willebrand disease
2010-024108-84Phase 3Completed
- Sponsor
- Baxter International Inc.
- Start
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of vonicog alfa in von Willebrand disease (VWD) (2 arms), sponsored by Baxter International Inc. Primary endpoint: Treatment success for bleeding episodes. Started Aug 2011; status: completed.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2010-024108-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024108-84.